High incidence of contaminating maternal cell overgrowth in human placental mesenchymal stem/stromal cell cultures: A systematic review

Stem Cells Translational Medicine

Volumn 3, Issue 11, 2014, Pages 1305-1312

  Heazlewood, Celena F ^a   Sherrell, Helen ^a   Ryan, Jennifer ^a   Atkinson, Kerry ^a,b   Wells, Christine A ^a,c   Fisk, Nicholas M ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chorion; Fetal; Maternal contamination; Mesenchymal stromal cell; Placenta; Stem cell

Indexed keywords

ARTICLE; CELL CULTURE; CELL GROWTH; CELL OVERGROWTH; CHORION; CLINICAL TRIAL (TOPIC); CONTAMINATION; FLUORESCENCE IN SITU HYBRIDIZATION; GESTATIONAL AGE; HUMAN; INCIDENCE; KARYOTYPING; MATERNAL CELL CONTAMINATION; MESENCHYMAL STEM CELL; PLACENTA; POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; ADULT; ADULT STEM CELL; CYTOLOGY; FEMALE; MESENCHYMAL STROMA CELL; METABOLISM; PREGNANCY;

ADULT; ADULT STEM CELLS; CHORION; FEMALE; HUMANS; MESENCHYMAL STROMAL CELLS; PLACENTA; PREGNANCY;

EID: 84908377160     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0051     Document Type: Article

References (51)

1. Millard SM, Fisk NM. Mesenchymal stem cells for systemic therapy: Shotgun approach or magic bullets? BioEssays 2013;35: 173-182.
2. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
3. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
4. Troeger C, Perahud I, Moser S, et al. Transplacental traffic after in utero mesenchymal stem cell transplantation. Stem Cells Dev 2010; 19:1385-1392.
5. Campagnoli C, Roberts IA, Kumar S, et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396-2402.
6. Götherström C, Ringdén O, Westgren M, et al. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 2003;32:265-272.
7. Roelen DL, van der Mast BJ, In’tanker PS, et al. Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Hum Immunol 2009;70:16-23.
8. Guillot PV, Gotherstrom C, Chan J, et al. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. STEM CELLS 2007;25:646-654.
9. Chan J, O’Donoghue K, Gavina M, et al. Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration. STEM CELLS 2006;24:1879-1891.
10. Dan YY, Riehle KJ, Lazaro C, et al. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci USA 2006;103:9912-9917.
11. Kennea NL, Waddington SN, Chan J, et al. Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype. Cell Cycle 2009;8:1069-1079.
12. Ramkisoensing AA, Pijnappels DA, Askar SF, et al. Human embryonic and fetal mesenchymal stem cells differentiate toward three different cardiac lineages in contrast to their adult counterparts. PLoS ONE 2011;6:e24164.
13. Portmann-Lanz CB, Schoeberlein A, Huber A., et al. Placental mesenchymal stem cells as potential autologous graft for pre-and perinatal neuroregeneration. Am J Obstet Gynecol 2006;194:664-673.
14. Lee HJ, Jung J, Cho KJ, et al. Comparison of in vitro hepatogenic differentiation potential between various placenta-derived stem cells and other adult stem cells as an alternative source of functional hepatocytes. Differentiation 2012;84:223-231.
15. Guillot PV, O’Donoghue K, Kurata H, et al. Fetal stem cells: Betwixt and between. Semin Reprod Med 2006;24:340-347.
16. Macias MI, Grande J, Moreno A, et al. Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers. AmJ Obstet Gynecol 2010;203:495.e9-495.e23.
17. Castrechini NM, Murthi P, Qin S, et al. Decidua parietalis-derivedmesenchymal stromal cells reside in a vascular niche within the choriodecidua. Reprod Sci 2012;19:1302-1314.
18. Nagan N, Faulkner NE, Curtis C, et al. Laboratory guidelines for detection, interpretation, and reporting of maternal cell contamination in prenatal analyses a report of the association for molecular pathology. J Mol Diagn 2011;13: 7-11.
19. Schrijver I, Cherny SC, Zehnder JL. Testing for maternal cell contamination in prenatal samples: A comprehensive survey of current diagnostic practices in 35 molecular diagnostic laboratories. J Mol Diagn 2007;9:394-400.
20. Parolini O, Alviano F, Bagnara GP, et al. Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international Workshop on Placenta Derived Stem Cells. STEM CELLS 2008;26:300-311.
21. Jones GN, Moschidou D, Puga-Iglesias TI, et al. Ontological differences in first compared to third trimester human fetal placental chorionic stem cells. PLoS ONE 2012;7: e43395.
22. Rus Ciucă D, Soriţău O, Suşman S, et al. Isolation and characterization of chorionic mesenchyal stem cells from the placenta. Rom J Morphol Embryol 2011;52:803-808.
23. Pluristem Therapeutics Inc. Clinical Program. March 2014. Available at http://www.pluristem.com/index.php/clinic-program.html.
24. Prather WR, Toren A, Meiron M. Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood. Expert Opin Biol Ther 2008;8:1241-1250.
25. Gaberman E, Pinzur L, Levdansky L, et al. Mitigation of lethal radiation syndrome in mice by intramuscular injection of3Dcultured adherent human placental stromal cells. PLoS ONE 2013;8:e66549.
26. Kranz A, Wagner DC, Kamprad M, et al. Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats. Brain Res 2010;1315:128-136.
27. Systematic Reviews: CRD’s Guidance for Undertaking Systematic Reviews in Health Care. York, U.K.: Centre for Reviews& Dissemination, 2009.
28. Moher D, Liberati A, Tetzlaff J, et al. Reprint— Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Phys Ther 2009;89:873-880.
29. Chen CP, Liu SH, Huang JP, et al. Engraftment potential of human placenta-derived mesenchymal stem cells after in utero transplantation in rats. Hum Reprod 2009;24:154-165.
30. Igura K, Zhang X, Takahashi K, et al. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy 2004;6:543-553.
31. Li C, Zhang W, Jiang X, et al. Humanplacenta-derived mesenchymal stem cells inhibit proliferation and function of allogeneic immune cells. Cell Tissue Res 2007;330:437-446.
32. Nazarov I, Lee JW, Soupene E, et al. Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:359-372.
33. Poloni A, Rosini V, Mondini E, et al. Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy 2008;10: 690-697.
34. Poloni A, Maurizi G, Babini L, et al. Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. Cell Transplant 2011;20:643-654.
35. Wang L, Yang Y, Zhu Y, et al. Characterization of placenta-derived mesenchymal stem cells cultured in autologous human cord blood serum. Mol Med Rep 2012;6:760-766.
36. Barlow S, Brooke G, Chatterjee K, et al. Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008;17:1095-1107.
37. Jaramillo-Ferrada PA, Wolvetang EJ, Cooper-White JJ. Differential mesengenic potential and expression of stem cell-fate modulators in mesenchymal stromal cells from human-term placenta and bone marrow. J Cell Physiol 2012; 227:3234-3242.
38. Ringdén O, Erkers T, Nava S, et al. Fetal membrane cells for treatment of steroidrefractory acute graft-versus-host disease. STEM CELLS 2013;31:592-601.
39. Semenov OV, et al. Multipotent mesenchymal stem cells from human placenta: Critical parameters for isolation and maintenance of stemness after isolation. Am J Obstet Gynecol 2010;202:193.e1-193.e13.
40. Soncini M, Vertua E, Gibelli L, et al. Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med 2007;1:296-305.
41. In’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. STEM CELLS 2004;22:1338-1345.
42. Strakova Z, Livak M, Krezalek M, et al. Multipotent properties of myofibroblast cells derived from human placenta. Cell Tissue Res 2008;332:479-488.
43. Wulf GG, Viereck V, Hemmerlein B, et al. Mesengenic progenitor cells derived from human placenta. Tissue Eng 2004;10:1136-1147.
44. Indumathi S, Harikrishnan R, Mishra R, et al. Comparison of feto-maternal organ derived stem cells in facets of immunophenotype, proliferation and differentiation. Tissue Cell 2013;45:434-442.
45. O’Donoghue K, Choolani M, Chan J, et al. Identification of fetal mesenchymal stem cells in maternal blood: Implications for noninvasive prenatal diagnosis. Mol Hum Reprod 2003;9:497-502.
46. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2000;2:477-488.
47. Seppanen E, Fisk NM, Khosrotehrani K. Pregnancy-acquired fetal progenitor cells. J Reprod Immunol 2013;97:27-35.
48. Chen CP, Lee MY, Huang JP, et al. Trafficking of multipotent mesenchymal stromal cells from maternal circulation through the placenta involves vascular endothelial growth factor receptor-1 and integrins. STEM CELLS 2008;26: 550-561.
49. Cvitic S, Longtine MS, Hackl H, et al. The human placental sexome differs between trophoblast epithelium and villous vessel endothelium. PLoS ONE 2013;8:e79233.
50. Clifton VL. Review: Sex and the human placenta: Mediating differential strategies of fetal growth and survival. Placenta 2010; 31(suppl):S33-S39.
51. Crisostomo PR, Markel TA, Wang M., et al. In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power. Surgery 2007;142:215-221.